Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC

Inclusion Criteria: 1. Patients must have: IIIA or IIIB non-small cell lung cancer by radiographic or surgical staging, excluding: superior sulcus tumors, tumors with associated atelectasis or obstructive pneumonitis of the entire lung, and tumors with a malignant pleural effusion. 2. Patients will be included in the study based on the following criteria: * Patients must be older than 18 years old. * Patients must have a Zubrod performance status of 0 to 2 * Patients with adequate bone marrow function * Patients with adequate renal function * Patients with adequate hepatic function * Patients of childbearing potential must have a negative serum pregnancy test and use an effective form of contraception. * Patients who are suitable for treatment with radical intent using concurrent chemotherapy and radiation. * Patients who have signed an approved informed consent and authorization permitting release of personal health information. Exclusion Criteria: 1. Disease-Specific Exclusions * Superior sulcus tumors * Atelectasis or obstructive pneumonitis of the entire lung * Malignant pleural effusion 2. General Medical Exclusions * Surgical candidates * Patients who are pregnant at the time of diagnosis * Serious concomitant systemic disorders incompatible with the study * Inability to comply with study and/or follow-up procedures * Life expectancy of less than 12 weeks * Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study * Patients with septicemia or severe infection. * Patients who have circumstances that will not permit completion of this study or the required follow-up * Patients with any contraindication to gemcitabine, carboplatin, or paclitaxel